Skip to main content
. 2019 Mar 21;10:165. doi: 10.3389/fendo.2019.00165

Figure 2.

Figure 2

Expression level of hsFLT1 protein in maternal blood serum as measured by ELISA (A) and expression of hsFLT1 mRNA in maternal liver (B) and kidney (C) as well as in placentas (D) and fetuses (E) as determined by qPCR of the hsFLT1/rtTA mouse model. Expression of human soluble fms-like tyrosine kinase 1 (hsFLT1) occurred only in the mice that exhibited induced hsFLT1/rtTA (reverse tetracycline-controlled transactivator) after treatment with doxycycline (+Dox) (FGR group) and that also exhibited higher placental and fetal hsFLT1 expression depending on the fetal rtTA genotype. Low hsFLT1 expression was detectable in FGR wild-type (wt) placentas and no hsFLT1 expression in FGR wt fetuses or in the control and Dox control groups. Samples were obtained from complete placentas and fetuses and from maternal livers and kidneys at day 18.5 post coitum (dpc). Measured mRNA levels were normalized to Gapdh. *p < 0.05, **p < 0.01 and ***p < 0.001, as determined by the Kruskal–Wallis test and Dunn's post hoc test.